Matthew W. Tikonoff
Mergers & Acquisitions
- Syncona Limited (LON: SYNC) in its acquisition of Applied Genetic Technologies Corporation (Nasdaq: AGTC)
- HouseWorks, a home health care provider, in connection with a majority equity investment by InTandem Capital Partners
- Philips Healthcare in connection with numerous mergers and acquisitions and other strategic transactions. Representative transactions include:
- Divestiture of Philips’ Aging and Caregiving (ACG) business
- Acquisition of Vesper Medical, Inc., a medical technology company that develops minimally-invasive peripheral vascular devices
- Acquisition of Intact Vascular, the maker of the Tack specialized implantable device for treating peripheral artery disease
- Acquisition of the teleradiology platform of Direct Radiology
- Acquisition of EPD Solutions, the innovator of a breakthrough cardiac imaging and navigation system
- Acquisition of Remote Diagnostics Technologies, a UK-based innovator of advanced solutions for the pre-hospital market providing monitoring, cardiac therapy and data management
- Acquisition of Blue Willow Systems, a cloud-based senior living community resident safety platform
- Acquisition of CardioProlific, a company developing catheter-based thrombectomy approaches to peripheral vascular disease
- Netsmart Technologies, a leading provider of healthcare Software as a Service (SaaS) technology and services solutions, in connection with numerous merger and acquisitions. Representative transactions include:
- Acquisition of Remarkable Health, an industry-leading provider of artificial intelligence technology and software solutions for behavioral health, substance use and human services organizations
- Acquisition of the entity owning TheraOffice, an industry-leading practice management platform for physical therapy and rehabilitation practices
- Acquisition of SimpleLTC, a data analytics and consulting services firm
- Acquisition of GPM, a Software-as-a-Service technology and services company
- Acquisition of Tellus, a provider of electronic visit verification (EVV), mobile care delivery and claims processing technology
- Acquisition of Quality In Real Time (QIRT), a post-acute health care consulting firm
- Acquisition of McBee Associates, a healthcare consulting firm
- Acquisition of Homecare Accounting Solutions, LLC, a cloud-based software company for home care agencies
- Acquisition of Devero, Inc., a healthcare technology company specializing in home healthcare and hospice
- Acquisition of HealthMEDX, a developer of electronic medical record (EMR) solutions
- Acquisition of Trend Consulting Services, a provider of information technology outsourcing and infrastructure support services
- Acquisition of Lavender & Wyatt Systems, a provider of enterprise behavioral health electronic medical records software and technology solutions
- Viela Bio (Nasdaq:VIE) in its $3.05 billion sale to Horizon Therapeutics (Nasdaq: HZNP), ranked in Fierce Biotech’s “The Top 10 Biopharma M&A Deals in 2021”
- F-Star Therapeutics in its reverse merger with Spring Bank Pharmaceuticals (Nasdaq: SBPH)
- Cheetah Medical, a provider of noninvasive hemodynamic monitoring devices, in connection with its sale to Baxter International Inc. (NYSE:BAX)
- Patriot Energy Group, a retail electricity and natural gas management firm, in its strategic alliance with EMEX, LLC
- Belmont Instrument Corporation, a leading provider of fluid warming infusion systems, in its recapitalization transaction with Audax Private Equity
- Jacqueline's Wholesale Bakery, Inc., a leading manufacturer of frozen cookie dough for the in-store bakery and foodservice channels, in connection with its sale to Rich Product Corporation
- Molecular Templates, Inc. in its merger with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
- Associated Home Care, a private-duty home health aide provider, in its sale to Amedisys (NASDAQ: AMED)
- Frazier Healthcare Ventures, a middle-market private equity firm, in its acquisition of a medical footware company
- SiOnyx, an image sensor and camera company specializing in low light and near infrared imaging, in its acquisition by a leading private equity firm and subsequent sale to DC Capital Partners
- Edgile, a cybersecurity consulting firm, in a minority investment transaction with a leading private equity firm
- A privately-held distributor of industrial supplies in its sale to a strategic competitor
- Essilor International, an eyewear company, in its acquisition of Costa (NASDAQ: ATX)
- FGX International, an eyewear company, in its acquisition of Stylemark
- Dynasil Corporation of America (NASDAQ: DYSL) in the sale of its cancer medical probe business to Dilon Technologies and the sale of its x-ray fluorescence lead paint detector business to Protec
- PTC (NASDAQ: PTC) in its acquisition of Enigma Information Systems
- Ampersand Capital Partners in its acquisitions of numerous portfolio companies
Securities Offerings
- Spero Therapeutics, Inc. (NASDAQ: SPRO) in its $75 million follow-on offering and its $10 million registered direct offering
- Spero Therapeutics, Inc. (NASDAQ: SPRO) in its $83.6 million initial public offering
- WAVE Life Sciences (NASDAQ: WVE) in its $102 million initial public offering
- Lamar Advertising Company (NASDAQ: LAMR) in Rule 144A debt offerings and follow-on exchange offers
- Stemline Therapeutics (NASDAQ: STML) in its $30 million initial public offering
Case Study
Mintz represented Spero Therapeutics, a clinical-stage biopharmaceutical company developing treatments for drug-resistant bacterial infections, in a September 2020 underwritten public offering that netted $80 million in gross proceeds before the deduction of underwriting discounts and commissions.
Case Study
Mintz advised biopharma company Spero Therapeutics on an agreement with Everest Medicines regarding the development and commercialization of a product to treat multidrug-resistant bacterial infections and option to license another.
Case Study
In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.